These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 21926399)
1. Two escalated followed by six standard BEACOPP in advanced-stage high-risk classical Hodgkin lymphoma: high cure rates but increased risk of aseptic osteonecrosis. Fosså A; Fiskvik IH; Kolstad A; Lauritzsen GF; Aurlien E; Blystad AK; Hole KH; Ikonomou IM; Holte H Ann Oncol; 2012 May; 23(5):1254-1259. PubMed ID: 21926399 [TBL] [Abstract][Full Text] [Related]
2. Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma. Skoetz N; Will A; Monsef I; Brillant C; Engert A; von Tresckow B Cochrane Database Syst Rev; 2017 May; 5(5):CD007941. PubMed ID: 28541603 [TBL] [Abstract][Full Text] [Related]
3. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group. Eichenauer DA; Plütschow A; Kreissl S; Sökler M; Hellmuth JC; Meissner J; Mathas S; Topp MS; Behringer K; Klapper W; Kuhnert G; Dietlein M; Kobe C; Fuchs M; Diehl V; Engert A; Borchmann P Lancet Oncol; 2017 Dec; 18(12):1680-1687. PubMed ID: 29133014 [TBL] [Abstract][Full Text] [Related]
4. Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin's Lymphoma Study Group. Tesch H; Diehl V; Lathan B; Hasenclever D; Sieber M; Rüffer U; Engert A; Franklin J; Pfreundschuh M; Schalk KP; Schwieder G; Wulf G; Dölken G; Worst P; Koch P; Schmitz N; Bruntsch U; Tirier C; Müller U; Loeffler M Blood; 1998 Dec; 92(12):4560-7. PubMed ID: 9845521 [TBL] [Abstract][Full Text] [Related]
5. Osteonecrosis detected by whole body magnetic resonance in patients with Hodgkin Lymphoma treated by BEACOPP. Albano D; Patti C; La Grutta L; Grassedonio E; Mulè A; Brancatelli G; Lagalla R; Midiri M; Galia M Eur Radiol; 2017 May; 27(5):2129-2136. PubMed ID: 27519911 [TBL] [Abstract][Full Text] [Related]
6. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. Borchmann P; Haverkamp H; Diehl V; Cerny T; Markova J; Ho AD; Eich HT; Mueller-Hermelink HK; Kanz L; Greil R; Rank A; Paulus U; Smardova L; Huber C; Dörken B; Nerl C; Krause SW; Mueller RP; Fuchs M; Engert A J Clin Oncol; 2011 Nov; 29(32):4234-42. PubMed ID: 21990399 [TBL] [Abstract][Full Text] [Related]
7. Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial. Carde P; Karrasch M; Fortpied C; Brice P; Khaled H; Casasnovas O; Caillot D; Gaillard I; Bologna S; Ferme C; Lugtenburg PJ; Morschhauser F; Aurer I; Coiffier B; Meyer R; Seftel M; Wolf M; Glimelius B; Sureda A; Mounier N J Clin Oncol; 2016 Jun; 34(17):2028-36. PubMed ID: 27114593 [TBL] [Abstract][Full Text] [Related]
8. Impact of Bleomycin and Vincristine Dose Reductions in Patients With Advanced Hodgkin Lymphoma Treated With BEACOPP: An Analysis of the German Hodgkin Study Group HD12 and HD15 Trials. Haverkamp H; Böll B; Eichenauer DA; Sasse S; Fuchs M; Borchmann P; Diehl V; Engert A; von Tresckow B J Clin Oncol; 2015 Aug; 33(22):2430-6. PubMed ID: 26101245 [TBL] [Abstract][Full Text] [Related]
9. Acute hematologic toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group (GHSG). Engel C; Loeffler M; Schmitz S; Tesch H; Diehl V Ann Oncol; 2000 Sep; 11(9):1105-14. PubMed ID: 11061603 [TBL] [Abstract][Full Text] [Related]
10. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study. Hentrich M; Berger M; Wyen C; Siehl J; Rockstroh JK; Müller M; Fätkenheuer G; Seidel E; Nickelsen M; Wolf T; Rieke A; Schürmann D; Schmidmaier R; Planker M; Alt J; Mosthaf F; Engert A; Arasteh K; Hoffmann C J Clin Oncol; 2012 Nov; 30(33):4117-23. PubMed ID: 23045592 [TBL] [Abstract][Full Text] [Related]
11. Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients. Dann EJ; Bairey O; Bar-Shalom R; Mashiach T; Barzilai E; Kornberg A; Akria L; Tadmor T; Filanovsky K; Abadi U; Kagna O; Ruchlemer R; Abdah-Bortnyak R; Goldschmidt N; Epelbaum R; Horowitz NA; Lavie D; Ben-Yehuda D; Shpilberg O; Paltiel O Br J Haematol; 2017 Sep; 178(5):709-718. PubMed ID: 28589704 [TBL] [Abstract][Full Text] [Related]
12. BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children's Oncology Group. Kelly KM; Sposto R; Hutchinson R; Massey V; McCarten K; Perkins S; Lones M; Villaluna D; Weiner M Blood; 2011 Mar; 117(9):2596-603. PubMed ID: 21079154 [TBL] [Abstract][Full Text] [Related]
13. Phase II study of interim PET-CT-guided response-adapted therapy in advanced Hodgkin's lymphoma. Ganesan P; Rajendranath R; Kannan K; Radhakrishnan V; Ganesan TS; Udupa K; Lakshmipathy KM; Mahajan V; Sundersingh S; Rajaraman S; Krishnakumar R; Sagar TG Ann Oncol; 2015 Jun; 26(6):1170-1174. PubMed ID: 25701453 [TBL] [Abstract][Full Text] [Related]
14. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group. Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V; J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249 [TBL] [Abstract][Full Text] [Related]
15. Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14). Gillessen S; Plütschow A; Fuchs M; Markova J; Greil R; Topp MS; Meissner J; Zijlstra JM; Eichenauer DA; Bröckelmann PJ; Diehl V; Borchmann P; Engert A; von Tresckow B Lancet Haematol; 2021 Apr; 8(4):e278-e288. PubMed ID: 33770483 [TBL] [Abstract][Full Text] [Related]
16. Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi. Merli F; Luminari S; Gobbi PG; Cascavilla N; Mammi C; Ilariucci F; Stelitano C; Musso M; Baldini L; Galimberti S; Angrilli F; Polimeno G; Scalzulli PR; Ferrari A; Marcheselli L; Federico M J Clin Oncol; 2016 Apr; 34(11):1175-81. PubMed ID: 26712220 [TBL] [Abstract][Full Text] [Related]
17. Spermatogenesis in Hodgkin's lymphoma patients: a retrospective study of semen quality before and after different chemotherapy regimens. Paoli D; Rizzo F; Fiore G; Pallotti F; Pulsoni A; Annechini G; Lombardo F; Lenzi A; Gandini L Hum Reprod; 2016 Feb; 31(2):263-72. PubMed ID: 26705149 [TBL] [Abstract][Full Text] [Related]
18. Advanced Hodgkin lymphoma in the East of England: a 10-year comparative analysis of outcomes for real-world patients treated with ABVD or escalated-BEACOPP, aged less than 60 years, compared with 5-year extended follow-up from the RATHL trial. Russell J; Collins A; Fowler A; Karanth M; Saha C; Docherty S; Padayatty J; Maw K; Lentell I; Cooke L; Hodson A; Shah N; Sadullah S; Grigoropoulos N; Qian W; Kirkwood AA; Uttenthal BJ; Johnson P; Follows GA Ann Hematol; 2021 Apr; 100(4):1049-1058. PubMed ID: 33641019 [TBL] [Abstract][Full Text] [Related]
19. Ten years' experience with four cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, procarbazine (BEACOPP)-escalated followed by four cycles of baseline-dose BEACOPP in patients with advanced stage Hodgkin lymphoma: a single-center, retrospective study. Belada D; Štěpánková P; Sýkorová A; Žák P; Smolej L Leuk Lymphoma; 2015 Jul; 56(7):2013-8. PubMed ID: 25330440 [TBL] [Abstract][Full Text] [Related]
20. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. Engert A; Diehl V; Franklin J; Lohri A; Dörken B; Ludwig WD; Koch P; Hänel M; Pfreundschuh M; Wilhelm M; Trümper L; Aulitzky WE; Bentz M; Rummel M; Sezer O; Müller-Hermelink HK; Hasenclever D; Löffler M J Clin Oncol; 2009 Sep; 27(27):4548-54. PubMed ID: 19704068 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]